Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zaleplon
Drug ID BADD_D02379
Description Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Indications and Usage For the treatment of short-term treatment of insomnia in adults.
Marketing Status approved; illicit; investigational
ATC Code N05CF03
DrugBank ID DB00962
KEGG ID D00530
MeSH ID C085665
PubChem ID 5719
TTD Drug ID D09DWL
NDC Product Code 29300-131; 71335-1054; 71335-1387; 43063-783; 57237-239; 42043-210; 57237-240; 68788-7208; 53296-0056; 65862-215; 71335-0236; 0054-0085; 63629-3405; 65862-214; 16436-0056; 42043-211; 0054-0084; 71335-1466; 51846-1026; 65862-197; 29300-132; 43063-505; 43063-912; 45865-541; 64330-054
UNII S62U433RMH
Synonyms zaleplon | 3'-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide | N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide | L 846 | L-846 | Zelepion | Starnoc | SKP-1041 | CL 284,846 | CL-284846 | CL284,846 | CL 284846 | Sonata
Chemical Information
Molecular Formula C17H15N5O
CAS Registry Number 151319-34-5
SMILES CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hiccups22.12.01.001; 07.01.06.009--
Hostility19.05.01.003--Not Available
Hyperacusis04.02.02.001; 17.04.03.003--Not Available
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.003--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hyperreflexia17.02.01.002--Not Available
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperuricaemia14.09.01.003--
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokinesia17.01.02.009--Not Available
Hyporeflexia17.02.01.003--
Hypotension24.06.03.002--
Hypothyroidism14.11.01.012; 05.02.03.001--
Hypotonia17.05.02.002; 15.05.04.008--Not Available
Immune system disorder10.02.01.001--Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal obstruction07.13.01.002--Not Available
Irritability08.01.03.011; 19.04.02.013--
Joint stiffness15.01.02.003--Not Available
Joint swelling15.01.02.004--Not Available
Ketosis14.01.01.001--Not Available
Labyrinthitis11.01.05.002; 04.04.03.001--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene